Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 4;1(4):282-287.
doi: 10.1182/bloodadvances.2016002493. eCollection 2017 Jan 10.

Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States

Luciano J Costa  1 , Ilene K Brill  2 , James Omel  3 , Kelly Godby  4 , Shaji K Kumar  5 , Elizabeth E Brown  6
Affiliations

Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States

Luciano J Costa et al. Blood Adv. .

Abstract

Prior improvements in multiple myeloma (MM) survival were not fully observed in racial and ethnic minorities and older individuals. We hypothesized that improvements in MM management in recent years have reduced these disparities. We used the Surveillance, Epidemiology, and End Results registries to calculate the incidence and relative survival rates (RSRs) of MM in the United States for patients diagnosed from 1993 to 1997 (prethalidomide), 1998 to 2002 (introduction of thalidomide), 2003 to 2007 (bortezomib and lenalidomide), and 2008 to 2012 (upfront bortezomib and lenalidomide, early availability of carfilzomib and pomalidomide). MM incidence increased significantly among non-Hispanic whites (NHWs) and non-Hispanic black (NHB) men, but not among NHB women and Hispanics. Improvement in 5-year RSRs (1993-1997 vs 2008-2012) was seen among patients of all age and race/ethnicity groups. Ten-year RSRs (1993-1997 vs 2003-2007) improved for patients <65 years of age (19.6%-35%; P < .001), but not for patients ≥75 years of age (7.8%-9.3%; P = .3). Among patients 65 to 74 years of age, 10-year RSRs improved for NHWs (11.3% vs 20.5%; P < .001) and Hispanics (10.6% vs 20.2%; P = .02), but not for NHBs (12.6% vs 19.5%; P = .06.). These findings confirm consistent improvement in survival for MM patients and point to the challenge of further extending these improvements to older and minority patients.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Changes in RSRs of patients diagnosed with MM in the United States grouped by sex, age, or race/ethnicity. Changes in RSR for all individuals (A), males (B), females (C), individuals diagnosed at age <65 years (D), individuals diagnosed at age 65 to 74 years (E), individuals diagnosed at age ≥75 years (F), NHW (G), NHB (H), and Hispanics (I) irrespective of age.
Figure 2.
Figure 2.
Changes in 5-year and 10-year relative survival of patients diagnosed with MM according to sex and race/ethnicity. Changes in 5-year and 10-year RSR for NHW (A), NHB (B), and Hispanics (C) according to sex.
Figure 3.
Figure 3.
Changes in 5-year and 10-year relative survival of patients diagnosed with MM according to age and race/ethnicity. Changes in 5-year and 10-year RSR for patients diagnosed at age <65 years (A), 65 to 74 years (B), and ≥75 years (C) according to race/ethnicity.
See this image and copyright information in PMC

References

    1. Kristinsson SY, Anderson WF, Landgren O. Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia. 2014;28(6):1346-1348. - PubMed
    1. Waxman AJ, Mink PJ, Devesa SS, et al. . Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010;116(25):5501-5506. - PMC - PubMed
    1. Ailawadhi S, Aldoss IT, Yang D, et al. . Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol. 2012;158(1):91-98. - PubMed
    1. Richardson PG, Sonneveld P, Schuster MW, et al. ; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487-2498. - PubMed
    1. San Miguel JF, Schlag R, Khuageva NK, et al. ; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917. - PubMed